Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Nov;8(7):2508-2509.
doi: 10.21037/tcr.2019.05.11.

Prostate radiotherapy for metastatic hormone sensitive prostate cancer-myth or reality?

Cem Onal  1
Affiliations
Editorial

Prostate radiotherapy for metastatic hormone sensitive prostate cancer-myth or reality?

Cem Onal. Transl Cancer Res. 2019 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.05.11). The author has no conflicts of interest to declare.

Comment on

References

    1. Fossati N, Trinh QD, Sammon J, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol 2015;67:3-6. 10.1016/j.eururo.2014.08.056 - DOI - PubMed
    1. Satkunasivam R, Kim AE, Desai M, et al. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J Urol 2015;194:378-85. 10.1016/j.juro.2015.02.084 - DOI - PMC - PubMed
    1. Yildirim BA, Onal C, Kose F, et al. Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Strahlenther Onkol 2019;195:872-81. 10.1007/s00066-019-01429-6 - DOI - PubMed
    1. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392:2353-66. 10.1016/S0140-6736(18)32486-3 - DOI - PMC - PubMed
    1. Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8. 10.1016/j.eururo.2018.09.008 - DOI - PubMed